Accelerating workflows for immunoassay and peptide researchers

Biotherapeutic development demands flexible and automated platforms that deliver accurate, replicable results at scale, from discovery to manufacture.

Our proven platforms deliver unmatched precision and efficiency

Achieve biotherapeutic development goals faster with automated platforms that ensure quality, throughput and data consistency.

Improving immunoassay workflows
Gyrolab immunoassays minimize sample and reagent volumes, reduce analysis time, and increase data quality across a wide variety of applications.

Advanced peptide synthesizers
Our advanced synthesis solutions empower you to synthesize any sequence with confidence, overcome productivity challenges, and accelerate your research.

Resource articles

Precision meets efficiency: Get insights into how Gyrolab and PurePep solutions innovate biotherapeutic drug development.

IMMUNOASSAYS
AN: Selective and robust biomarker quantification using Gyrolab human cytokine kit reagents
This application note guides research scientists in using Gyrolab® single-analyte cytokine assays for fast, automated, and robust biomarker quantification. Detection of 5 human cytokines, IL-4, IL-6, IL-10, IFN-gamma, and TNF-alpha in single-analyte automated assays on the Gyrolab platform evaluating selectivity.](/content/immunoassays/selective-and-robust-biomarker-quantification-gyrolab-kit-reagents/index.html)

PEPTIDES
Three bottlenecks slowing down your peptide purification workflow
Discover how HPLC delays, precipitation issues, and high costs slow peptide purification—plus a precipitation-free solution that saves 3-4 days per cycle.](/content/purepep-blog/3-peptide-purification-bottlenecks-slowing-your-research-purepep-blog/index.html)

%20(1).png?width=228&height=158&name=Blog%20automated%20immuoassays%20(2)%20(1).png)
IMMUNOASSAYS
Choosing the Right Automated Immunoassay Platform for Your Analytical Needs
Choose the ideal automated immunoassay platform by balancing flexibility, precision, and scalability to enhance your bioprocess workflows and regulatory compliance.](/content/spinblog/choosing-the-right-automated-immunoassay-platform-for-your-bioprocess-needs/index.html)

PEPTIDES
In-house peptide synthesis reduces costs and shortens turnaround times | Case Study with Ab Biotechnology
Discover how Ab Biotechnology cut timelines by 50% and achieved a 2-year ROI by adopting in-house peptide synthesis with Gyros Protein Technologies.](/content/purepep-blog/in-house-peptide-synthesis-reduces-costs-and-shortens-turnaround-times/index.html)

.png?width=228&height=158&name=The%20golden%20age%20of%20peptide%20therapeutics%20(1).png)
PEPTIDES
The Golden Age of Peptide Therapeutics: Insights from CatSci’s Simon Tyler
Discover why we're in the golden age of peptide therapeutics with insights from CatSci's Simon Tyler on market trends and the future of peptide science.](/content/purepep-blog/the-golden-age-of-peptide-therapeutics-expert-insights-purepep-blog/index.html)

IMMUNOASSAYS
Your guide to miniaturized immunoassays for biotherapeutics
Discover the advantages of automated, miniaturized immunoassays across
the drug development pathway from pre-clinical to bioprocessing](https://read.paperflite.com/assets/68d264fd6ef61d0385c68a9e?utm_source=Paperflite%20Link)

PEPTIDES
From Lab to Scale: A Game-Changing Approach to Peptide Purification in GLP-1 Manufacturing
Discover how innovative PEC technology transforms GLP-1 peptide manufacturing, offering a cost-effective alternative to traditional purification methods.](/content/purepep-blog/from-lab-to-scale-a-game-changing-approach-to-peptide-purification-in-glp-1-manufacturing/index.html)

IMMUNOASSAYS
Increasing productivity in cell and gene therapy bioprocessing with fast and reliable immunoassays
This white paper provides an overview of the viral vector landscape and its use in cell and gene therapy, with a focus on lentiviral vectors and adeno-associated viral (AAV) vectors.](https://read.paperflite.com/assets/68d264fd6ef61d0385c68a9e?utm_source=Paperflite%20Link)

IMMUNOASSAYS
Article - Development of anti-AAV assay for detection of pre-existing AAV immunity
This article presents an assay to detect pre-existing AAV immunity of subjects in pre-clinical studies, aiding subject selection and improving gene therapy research efficiency.](/content/immunoassays/development-of-anti-aav-assay-for-detection-of-pre-existing-aav-immunity/index.html)

IMMUNOASSAYS
AN: Accelerate throughput in therapeutic antibody development with an improved generic PK assay
This application note helps research scientists optimize preclinical pharmacokinetics studies by highlighting improved assay flexibility, sensitivity, and sample efficiency using the Gyrolab® 2G Generic PK Kit](/content/immunoassays/accelerate-throughput-intherapeutic-antibody-developmentwith-an-improved-generic-pk-assay/index.html)

IMMUNOASSAYS
White Paper: Anti-drug antibody studies
Learn how to maximize drug tolerance and minimize sample and reagent consumption](https://read.paperflite.com/assets/68d264fd6ef61d0385c68a9e?utm_source=Paperflite%20Link)

Over 30 years of excellence

Trusted by laboratories worldwide, we have enabled scientists to drive progress of biotherapeutic drug development from discovery through development to manufacture for over 30 years. Since 2019, Gyros Protein Technologies is a division of Mesa Labs, a growing confederation of leading-edge brands dedicated to "Protecting the Vulnerable®."